Atreca is a biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-Âcancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atrecaâs proprietary Immune Repertoire CaptureÂŽ technology profiles a patientâs immune response at the single-Âcell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. Source
No articles found.
Novocure is a global oncology company working to extend survival in some of the mo...
Novocure is a global oncology company working t...
Intrexon Corporation (NASDAQ: XON) is Powering the Bioindustrial Revolution with B...
Intrexon Corporation (NASDAQ: XON) is Powering ...
Aquestive Therapeutics is a specialty pharmaceutical company that advances and com...
Aquestive Therapeutics is a specialty pharmaceu...
Amphastar Pharmaceuticals, Inc., headquartered in Rancho Cucamonga, California, es...
Amphastar Pharmaceuticals, Inc., headquartered ...
Founded on September 28, 2005 through the merger of Daiichi Pharmaceutical and San...
Founded on September 28, 2005 through the merge...
Caladrius is a clinical-stage biopharmaceutical company committed to the developme...
Caladrius is a clinical-stage biopharmaceutical...
We are a biopharmaceutical company dedicated to the development of programmed cell...
We are a biopharmaceutical company dedicated to...
Join the National Investor Network and get the latest information with your interests in mind.